ArticleAmerican journal of cancer research2025
IL-33 as a biomarker for disease severity in COPD with lung cancer comorbidity.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the differences in peripheral blood levels of interleukin-1β (IL-1β), IL-6, IL-17, and IL-33 between patients with chronic obstructive pulmonary disease (COPD) and lung cancer (Comorbidity Group) and those with COPD alone (COPD Group), as well as to explore their clinical significance.
methodsSamples were collected from 133 patients with both COPD and lung cancer (Comorbidity Group) and 91 patients with COPD alone (COPD Group), diagnosed at Affiliated Hospital of Inner Mongolia Medical University between January 2022 and January 2024. Baseline data from both groups were analyzed, and peripheral blood levels of IL-1β, IL-6, IL-17, and IL-33 were measured using enzyme-linked immunosorbent assay (ELISA). The levels of these inflammatory cytokines were compared between the two groups to assess their correlation with disease severity.
resultsSignificant differences were observed between the Comorbidity Group and the COPD Group in terms of age (P<0.001), sex (P=0.012), duration of COPD (P=0.001), smoking history (P=0.006), glucocorticoid treatment (P=0.014), and GOLD Staging (P<0.001). IL-1β was positively correlated with RV/TLC (P=0.036), and IL-17 with FEV1 (P=0.027) in both groups. IL-6 was positively correlated with TLC in the Comorbidity Group (P=0.021). In the COPD Group, IL-33 was negatively correlated with FEV1 (P<0.001), FVC (P=0.001), FEV1/FVC (P<0.001), RV (P<0.001), and RV/TLC (P<0.001), and positively correlated with GOLD Staging (P=0.046). Multivariate logistic regression identified smoking history (P=0.045, OR=2.891), GOLD staging (P=0.028, OR=0.363), IL-33 (P=0.001, OR=27.369), FEV1/FVC (P=0.012, OR=4.291), RV (P=0.002, OR=5.429), and RV/TLC (P=0.002, OR=6.113) as independent factors distinguishing patients with comorbid COPD and lung cancer from those with COPD alone. Interaction analysis revealed no significant interaction between IL-33 and other risk factors.
conclusionIL-33 levels were significantly higher in patients with comorbid COPD and lung cancer than in those with COPD alone. IL-33 was negatively correlated with lung function and positively correlated with GOLD Staging, suggesting its potential as a biomarker for disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.